Article
Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
International journal of oncology - 1 Dec 2022
Guo Huihui, Zhang Xilin, Xie Shangzhi, Chen Tianwei, Xie Dong, Cai Ying, Cui Dawei, Wang Liang, Chen Wei, Wang Xiang
Abstract excerpt
Gefitinib is a sensitive and effective drug to treat non‑small‑cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR‑mutated NSCLC cells was discovered using in vitro co‑culture of NSCLC cells with peripheral blood mononuclear cells (PBMCs). Gefitinib...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Humans
- Immunity
- Leukocytes, Mononuclear
- Lung Neoplasms